We know now that the old iron chelators harm the brain ( Deferiprone in PD and AD studies). Most likely they also harm the mitochondrial energy production of other tissues, but evidently, there is also some benefit to the patients. Today, their market is some 800 million (https://reports.valuates.com/market-reports/QYRE-Auto-8W13226/global-iron-chelation-therapy).
Those who need iron chelation, use it often and for a long time because of their chronic problem. I cannot see that their brains could avoid these same adverse effects as has been seen in the PD and AD studies.
The 201 and 202 studies will demonstrate that iron concentration in the brain will become smaller ( was listed as the main outcome measure). In spite of it is not measured in these 434 studies corresponding decrease in iron will happen in other organs if there is iron overload.
So I expect that this $800m market will gradually be overtaken by a more physiological iron chelator 434.
I am very hopeful that we get positive results in the 201 study but I also think that the old iron chelator market will change to more physiological iron chelators and favor ATH.
ATH Price at posting:
0.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)